Lin BioScience, Inc.

6696

TW0006696008

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
93.1 ^TWD	+18.90%		+25.81%	-18.33%

Apr. 23	Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

April 25, 2023 at 03:55 am EDT

Lin BioScience, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was TWD 313.52 million compared to TWD 434.7 million a year ago. Basic loss per share from continuing operations was TWD 4.37 compared to TWD 6.32 a year ago.

Latest news about Lin BioScience, Inc.

Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-24	CI
Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-13	CI
Lin Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-06	CI
Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-07	CI
Lin BioScience, Inc.(GTSM:6696) added to S&P Global BMI Index	20-09-21	CI
Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-13	CI
Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-28	CI
Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-13	CI
Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-25	CI
US Food and Drug Administration Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease	18-09-17	CI

Chart Lin BioScience, Inc.

Duration

Period

More charts

Company Profile

LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIN BIOSCIENCE, INC.	-18.33%	224M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B